CRT-109 Clinical Outcomes Comparison Between First- And Second-generation Drug-eluting Stents In Octogenarians With Acute Myocardial Infarction  by Tian, Wenjie et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 8 , N O . 2 , S U P P L S , 2 0 1 5 S11
C
O
R
O
N
A
R
YThe aim of this study was to determine whether there are differences between non-
ST- and ST-segment elevation myocardial infarction (STEMI) for octogenarians un-
derwent DES implantation.
METHODS Clinical data of 164 octogenarians with STEMI (n¼115) or non-STEMI
(n¼49) who received the treatment of DES were retrospectively analyzed. The pri-
mary endpoint was the rate of major adverse cardiac events (MACE).
RESULTS The octogenarians with STEMI or non-STEME had similarly low ejection
fraction (EF, 0.420.16 vs. 0.430.18, p¼719) and comparatively high percentage of
chronic renal insufﬁciency (23.4% vs. 25.7%, p¼0.764). The patients with STEMI had
higher in-hospital, but similar out-hospital occurrence of cardiac death compared to
those with non-STEMI. There were no differences in rates of MACE (26.5% vs. 24.6%,
p¼0.790), all cause death (22.4% vs. 19.3%, p¼0.646) and TLR (5.0% vs. 6.9%,
p¼1.000) between the two groups at 1 year follow-up.
CONCLUSIONS The occurrence of MACE, mainly driven by all cause death, was high
in octogenarians with AMI underwent DES. The octogenarians with STEMI had higher
risk of in-hospital cardiac death, but comparable clinical outcomes compared to those
with non-STEMI at 1 year follow-up.
Table I. In-hospital, 1-year clinical outcomesVariableNon-STEMI
(n[115)STEMI
(n[49) p- valueClinical success (%) 95.7 83.7 0.022in-hospital Death 2.6 16.3% 0.003in-hospital Cardiac death 2.6 14.3 0.0081 year follow-up (%)MACE 24.6 26.5 0.790Death 19.3 22.4 0.646Cardiac death 7.0 18.4 0.028Cardiac death out-hospital 4.5 4.9 1.000Q-wave MI 0 0 _TLR 6.9 5.0 1.000Stent thrombosis 0.9 0 1.000MACE: Major adverse cardiac events; MI: Myocardial infarction; TLR: Target lesion revascularization
CRT-109
Clinical Outcomes Comparison Between First- And Second-generation
Drug-eluting Stents In Octogenarians With Acute Myocardial Infarction
Wenjie Tian, Rebecca Torguson, Ricardo Escarcega Alarcon,
Marco De Magalhaes Pereira, Thibault Lhermusier, Nevin Baker, Hideaki Ota,
Ron Waksman
MedStar Washington Hospital Center, Washington, DC
BACKGROUND Coronary intervention is infrequently performed in octogenarians and
the clinical outcomes of drug-eluting stents (DES) in octogenarians with acute
myocardial infarction (AMI) are limited. The aim of this study was to determine
whether there are differences between the ﬁrst- and second-generation DES for oc-
togenarians with AMI.
METHODS Clinical data of 164 octogenarians with AMI who underwent ﬁrst-genera-
tion DES (n¼104, 167 lesions) or second-generation DES (n¼60, 86 lesions) implan-
tation were retrospectively analyzed. The primary endpoint was the rate of major
adverse cardiac events (MACE) at 1 year follow-up.
RESULTS Baseline clinical and procedural characteristics were similar between the
two groups, except for less left main lesions (3.6% vs. 10.5%, p¼0.027) and greater
stent length (20.068.29mm vs. 16.164.85mm, p<0.001) in the ﬁrst-generation DES
group. The clinical success rate was similar in the two groups (89.4% vs. 96.7%,
p¼0.136). Compared with second-generation DES group, there were no differences in
the occurrence of MACE (27.2% vs. 21.7%, p¼0.434), TLR (5.7% vs. 7.4%, p¼1.000) and
all-cause death (23.3% vs. 15.0%, p¼0.203) in the second-generation DES group at 1-
year follow-up. The occurrence of stent thrombosis was similar (1% vs. 0%, p¼1.000)
in the two groups.
CONCLUSIONS The occurrence of MACE, mainly driven by all-cause death, was high
in octogenarians with AMI. The ﬁrst- and second-generation DES resulted in com-
parable outcomes at 1 year follow-up.Table I. 6-month and 1-year clinical outcomesVariable1-st generation DES
(n[104, 167 lesions)2-nd generation DES
(n[60, 86 lesions) p- value6 months follow-up (%)MACE 18.3 15.0 0.592All cause death 17.3 10.0 0.202Cardiac death 12.5 3.3 0.019Q-wave MI 1.1 3.6 0.556TLR 2.1 5.4 0.362Stent thrombosis 1.0 0 1.0001 year follow-up (%)MACE 27.2 21.7 0.434All cause death 23.3 15.0 0.203Cardiac death 12.5 6.6 0.171Q-wave MI 1.1 5.6 0.154TLR 5.7 7.4 1.000Stent thrombosis 1.0 0 1.000MACE: Major adverse cardiac events; MI: Myocardial infarction; TLR: Target lesion revascularizationCRT-110
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BACKGROUND Elevated left ventricular end-diastolic pressure (LVEDP) has been
shown to predict adverse outcomes in patients with ST elevation myocardial infarc-
tion. However, the prognostic value of elevated LVEDP in patients with non-ST
elevation myocardial infarction (NSTEMI) has not been fully elucidated.
METHODS We performed a retrospective analysis of 481 consecutive patients pre-
senting with NSTEMI who underwent coronary angiography within ﬁve days after
presentation from January 2013 to June 2014. LVEDP was measured during the index
cardiac catheterization. Patients without LVEDP data were excluded. Patients were
categorized into an elevated LVEDP group and control group. Baseline and angio-
graphic characteristics, in-hospital revascularization procedures as well as in-hospital
and 30-day major adverse cardiac event (MACE) including death, recurrent myocardial
infarction, and target vessel revascularizationwere compared between the two groups.
RESULTS LVEDP was measured in 367 patients. The median LVEDP was 19.0 mm Hg
(interquartile; 14.0, 24.0 mmHg). By receiver operating characteristic curve analysis,
the optimal cutoff value in predicting in-hospital MACE was 22 mmHg (area under the
curve was 0.80). As a result, 109 patients (29.7%) were categorized into the elevated
LVEDP group. Patients with elevated LVEDP were more likely to have hypertension
(79.8% vs. 69.0%, p¼0.03) and diabetes mellitus (50.5% vs. 32.9%, p¼0.002). There
was no signiﬁcant difference in the rates of multivessel disease, impaired coronary
blood ﬂow, in-hospital percutaneous coronary intervention and coronary artery
bypass grafting. Patients with elevated LVEDP had a higher rate of in-hospital heart
failure (22.0% vs. 13.2%, p¼0.03), in-hospital MACE (4.6% vs. 0.4%, p¼0.01) as well as
30-day MACE (8.3% vs. 2.7%, p¼0.02) compared with the control group. There was no
signiﬁcant difference in the rates of in-hospital heart failure, and in-hospital and 30-
day MACE between those with and without LVEDP measurements.
CONCLUSION Elevated LVEDP was signiﬁcantly associated with a higher rate of in-
hospital heart failure, in-hospital MACE and 30-day MACE in patients with NSTEMI.
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BACKGROUND Deeply inverted or biphasic T-waves in anterior leads, so-called
Wellens’ sign, has been considered to represent impending ischemia in left anterior
descending (LAD) territory. However, this electrocardiographic pattern may be
observed in patients without a critical stenosis in LAD artery. We aimed to evaluate its
prevalence, clinical signiﬁcance and prognostic value of Wellens’ sign in patients with
non-ST elevation myocardial infarction (NSTEMI).
METHODS We performed a retrospective analysis of 481 consecutive patients pre-
senting with NSTEMI who underwent coronary angiography within ﬁve days after
presentation. Patients with complete bundle branch block and ventricular paced
rhythm were excluded. Electrocardiograms were interpreted in a blinded fashion.
Wellens’ sign was deﬁned as either there are deeply inverted T-waves (3.0mV) or
biphasic T-waves in both lead V2 and V3. Patients were categorized into a Wellens
